Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
41.01
+0.14 (0.34%)
At close: Feb 6, 2026, 4:00 PM EST
40.82
-0.19 (-0.46%)
After-hours: Feb 6, 2026, 7:57 PM EST
Moderna Revenue
Moderna had revenue of $1.02B in the quarter ending September 30, 2025, a decrease of -45.44%. This brings the company's revenue in the last twelve months to $2.23B, down -56.07% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$2.23B
Revenue Growth
-56.07%
P/S Ratio
7.12
Revenue / Employee
$384,828
Employees
5,800
Market Cap
16.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | 60.00M | -75.07M | -55.58% |
| Dec 31, 2018 | 135.07M | -70.76M | -34.38% |
| Dec 31, 2017 | 205.83M | 97.43M | 89.88% |
| Dec 31, 2016 | 108.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 4.81B |
| Genmab | 3.85B |
| BioMarin Pharmaceutical | 3.09B |
| Exelixis | 2.29B |
| Ionis Pharmaceuticals | 966.96M |
| Ascendis Pharma | 758.59M |
| BridgeBio Pharma | 353.78M |
| Avidity Biosciences | 20.87M |
MRNA News
- 2 days ago - Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. - GlobeNewsWire
- 7 days ago - Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today? - Seeking Alpha
- 7 days ago - Moderna CMO Jacqueline Miller to step down - Reuters
- 7 days ago - Dr. David Berman to Join Moderna as Chief Development Officer - Accesswire
- 8 days ago - RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA - GlobeNewsWire
- 8 days ago - Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927) - Accesswire
- 11 days ago - Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026 - Accesswire
- 15 days ago - MRNY: Jumping On Big Moderna Move - Seeking Alpha